GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+13.98%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$174M
AUM Growth
+$174M
(-16%)
Cap. Flow
-$67M
Cap. Flow
% of AUM
-38.56%
Top 10 Holdings %
Top 10 Hldgs %
45.29%
Holding
75
New
12
Increased
13
Reduced
18
Closed
26
Top Buys
| 1 |
Biohaven
BHVN
|
$11.8M |
| 2 |
Roivant Sciences
ROIV
|
$6.02M |
| 3 |
Sarepta Therapeutics
SRPT
|
$5.79M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$5.26M |
| 5 |
argenx
ARGX
|
$4.76M |
Top Sells
| 1 |
MoonLake Immunotherapeutics
MLTX
|
$15.1M |
| 2 |
TG Therapeutics
TGTX
|
$12.8M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$9.83M |
| 4 |
Ascendis Pharma
ASND
|
$8.19M |
| 5 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$7.6M |
Sector Composition
| 1 | Healthcare | 99.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RVNC
26
DELISTED
Revance Therapeutics, Inc.
RVNC
| $3.3M | 1.08% |
375,000
+25,000
| +7% | +$220K |
|
27
Protagonist Therapeutics
PTGX
$3.62B
| $2.87M | 0.94% |
125,000
-275,000
| -69% | -$6.31M |
|
28
Astria Therapeutics
ATXS
$372M
| $2.57M | 0.84% |
335,000
+35,000
| +12% | +$269K |
|
|
29
Ascendis Pharma
ASND
$12.1B
| $2.52M | 0.82% |
20,000
-65,000
| -76% | -$8.19M |
|
30
Arvinas
ARVN
$580M
| $2.44M | 0.8% |
+59,250
| New | +$2.44M |
|
31
Crinetics Pharmaceuticals
CRNX
$3.26B
| $2.31M | 0.76% |
65,000
-36,443
| -36% | -$1.3M |
|
32
PMV Pharmaceuticals
PMVP
$82.1M
| $2.25M | 0.73% |
725,000
+19,119
| +3% | +$59.3K |
|
33
Natera
NTRA
$23B
| $2.19M | 0.72% |
+35,000
| New | +$2.19M |
|
|
CBAY
34
DELISTED
Cymabay Therapeutics
CBAY
| $2.13M | 0.7% |
+90,000
| New | +$2.13M |
|
35
KalVista Pharmaceuticals
KALV
$713M
| $1.59M | 0.52% |
130,036
+30,036
| +30% | +$368K |
|
36
Acadia Pharmaceuticals
ACAD
$4.34B
| $1.57M | 0.51% |
50,000
-30,000
| -38% | -$939K |
|
|
MRNS
37
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $1.47M | 0.48% |
+135,000
| New | +$1.47M |
|
|
INBX
38
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $1.33M | 0.43% |
35,000
| – | – |
|
39
Cogent Biosciences
COGT
$1.83B
| $1.15M | 0.37% |
195,000
-455,000
| -70% | -$2.68M |
|
40
uniQure
QURE
$954M
| $1.12M | 0.37% |
165,000
-50,000
| -23% | -$339K |
|
41
Cytokinetics
CYTK
$5.98B
| $835K | 0.27% |
10,000
-80,000
| -89% | -$6.68M |
|
42
Perspective Therapeutics
CATX
$251M
| $643K | 0.21% |
+160,000
| New | +$643K |
|
|
BLUE
43
DELISTED
bluebird bio
BLUE
| $642K | 0.21% |
+23,250
| New | +$642K |
|
|
VRNA
44
Verona Pharma
VRNA
$9.18B
| $596K | 0.2% |
30,000
-15,000
| -33% | -$298K |
|
45
Ventyx Biosciences
VTYX
$184M
| – | – |
-35,000
| Closed | -$1.22M |
|
46
SPDR S&P Biotech ETF
XBI
$5.29B
| – | – |
0
| – | – |
|
47
Xenon Pharmaceuticals
XENE
$2.99B
| – | – |
-98,951
| Closed | -$3.38M |
|
48
Zentalis Pharmaceuticals
ZNTL
$123M
| – | – |
-100,000
| Closed | -$2.01M |
|
49
Acumen Pharmaceuticals
ABOS
$82.4M
| – | – |
-150,000
| Closed | -$623K |
|
50
Akero Therapeutics
AKRO
$3.65B
| – | – |
-115,000
| Closed | -$5.82M |
|